Articles

ThromboGenics, a biotechnology company focused on vascular diseases, has completed patient enrolment for a Phase IIa trial designed to evaluate the safety and efficacy of microplasmin for the treatment of vitreomacular traction, including macular holes.

A thermosensitive glue for retinal implants provides an effective in vitro retinal adhesion that is completely reversible by lowering the temperature.

Results of an international survey have found that the majority of people aged over 40 years of age do not attend eye examinations.

QLT has entered into an agreement to acquire the privately held ForSight Newco II. The acquisition includes ForSight's proprietary ocular punctal plug drug delivery system.

Alacrity Biosciences has announced positive results from a Phase II study of its treatment for dry eye, ALTY-0501.

Patients at risk of advanced age-related macular degeneration (AMD) progression may benefit from consuming a smaller amount of refined carbohydrates.

People with high blood levels of C-reactive protein may be at higher risk of developing age-related macular degeneration.

Patients with central retinal vein occlusion (CRVO) who are treated early with intravitreal bevacizumab experience a dramatic improvement in visual acuity (VA) and clinical fundus appearance, without collateral vessel formation.

MacuSight has announced positive interim data from a Phase I study of its proprietary formulation of sirolimus (originally known as rapamycin) for the treatment of chronic, clinically significant diabetic macular oedema (DME).

The corneal stroma has the ability to clear microorganisms introduced during LASIK.

Repeat injections of bevacizumab are well tolerated; Bevacizumab reduces DME in the short-term; Unveiling a new clinical entity; Pupil dilation linked to glaucoma progression; Glaucoma scales fail to impress; New glaucoma progression predictors; Central vision loss & trabeculectomy; UK optometrists given prescribing powers; Higher retinal re-attachment success in patients with complete PVD; Every other year screening for retinopathy; A new approach for analysing patient compliance.

Persistent placoid maculopathy has features resembling macular serpiginous choroiditis but differs in its clinical course and effect on visual acuity.

Lower systolic perfusion pressure, lower systolic blood pressure and cardiovascular disease history are all predictors of glaucoma.

The desired refractive outcome is approximately 2 D by age two and 1 to 2 D by age three, reflecting the fact that the majority of growth of the eye has occurred by this age

We speak with Ivo Kocur of the World Health Organization who tells us how Vision 2020 is helping to reduce avoidable blindness in children around the world.

In patients with advanced visual field loss undergoing trabeculectomy with mitomycin C, there is a risk of severe loss of central vision.

...The eyes were generally not inflamed and achieved their maximum visual potential in a matter of weeks as opposed to the many months required for rehabilitation following a corneal transplant

Optometrists in the UK will soon be given the power to prescribe drugs for conditions such as dry eye.

In patients with open-angle glaucoma (OAG), the increase in intraocular pressure (IOP) caused by pharmacological pupillary dilation is related to the likelihood of future progression of glaucoma.

Repeat intravitreal injections of bevacizumab (off-label Avastin) for diseases such as proliferative diabetic retinopathy (DR), diabetic macular oedema (DME), retinal vein occlusions and choroidal neovascularization (CNV) appear to be safe and well tolerated.

Subspecialty training courses in ophthalmology are often subject to criticism because of the lack of detail that is provided to students wanting to specialise in a particular area.

Carl Zeiss to acquire Acri.Tec; B&L and Alcon settle dispute amicably; Alcon amends tender offer for Wavelight.

Carl Zeiss Meditec has announced that it intends to acquire Acri.Tec.

Every other year screening for diabetic eye disease appears to be both safe and effective in patients with diabetes without retinopathy.

The presence of a complete posterior vitreous detachment (PVD) may be associated with an increased likelihood for primary anatomic success following retinal detachment surgery in phakic eyes.

Welcome to the October issue of OTE and the second anniversary edition of our magazine. Two years ago this month saw the first issue of OTE hit desks across Europe.

Bausch & Lomb and Alcon have settled a lawsuit that was filed recently regarding Alcon's promotional claims about Bausch & Lomb's ReNu MultiPlus solution.

A gap analysis approach may be preferable to Kaplan-Meier survival curves for analysing patient persistence with prescribed medications.

Intravitreal bevacizumab can reduce diabetic macular oedema (DME) in some eyes, but a Phase III trial is required to determine whether the treatment is beneficial in the long-term.

Read Ophthalmology Times Europe's extensive coverage from the 2007 annual meeting in Stockholm, Sweden.